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Other names: NES1; PRSSL1 
Location: 19q13.41 
Local order: Telomere to centromere. 
DNA/RNA 
Description 
Spanning 5.7 kb of genomic DNA, the KLK10 gene 
consists of 5 introns and six exons. 
Transcription 
The KLK10 gene has several splice variants with 
different lengths of the first exon. The predominant 
form is 1443 bp. Since the first exon is untranslated, all 
splice variants encode the same protein. 
Pseudogene 
Not identified so far. 
Protein 
Description 
KLK10 is a 30 kDa serine protease containing 276 
amino acids. It consists of a signal peptide (aa 1-33), an 
activation peptide (aa 34-42), and a mature chain (aa 
43-276). 
Expression 
High levels of KLK10 expression are typically found in 
glandular epithelia in a wide variety of organs, such as 
salivary gland, gastrointestinal tract, prostate, lung, 
breast, and ovary. 
Localisation 
KLK10 is synthesized as a precursor protein of 276  
amino acids. Within the secretary pathway, its signal 
peptide is cleaved and it is secreted into the 
extracellular milieu as an inactive zymogen. 
KLK10 has been identified in many biological fluids, 
such as blood, amniotic fluid, cerebrospinal fluid, milk, 
and nipple aspirate. 
Function 
How KLK10 is activated remains undetermined. It is 
expected that upon activation, the peptide bond 
between arginine42 and lysine43 is proteolysed to 
release the mature chain. Mature KLK10 exhibits some 
typical characteristics of a trypsin-like serine protease, 
such as the catalytic triad (Histidine86, serine229, and 
aspartic acid137) and an aspartic acid in its substrate-
binding pocket. However, its enzymatic activity has not 
been experimentally confirmed so far. Consequently, 
its potential physiologic substrates have not been 
identified. 
Homology 
Human KLK10 shares 98.2% and 69% identity with 
chimpanzee and mouse/rat klk10, respectively. 
Mutations 
Note: No germinal or somatic mutations are identified 
to be associated with cancer so far. 
Implicated in 
Various cancers with upregulated 
KLK10 
Disease 
Epithelial ovarian carcinoma, uterine serous papillary 
carcinoma, head and neck squamous cell carcinoma, 
lung squamous cell carcinoma, and gastrointestinal 
tract cancer. 
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Prognosis 
In these malignancies, KLK10 has been reported to be 
upregulated. Among them, epithelial ovarian carcinoma 
is by far studied the most. KLK10 is overexpressed in 
ovarian tumor tissue than in normal epithelium and 
stromal tissues both at the mRNA and protein levels. 
Due to increased leakage of KLK10 into the 
circulation, serum concentrations of KLK10 in ovarian 
cancer patients are elevated. High levels of KLK10 in 
tumor tissue or in serum are associated with more 
advanced disease stages and poor survival. In 
particular, preoperative serum KLK10 levels can serve 
as a complimentary biomarker for CA125, a well-
established tumor marker routinely used in ovarian 
cancer. It has been demonstrated that nearly all CA125-
negative tumors show KLK10 immunostaining 
positivity and that about 35% of CA125-negative 
patients have increased serum levels of KLK10. In 
combination with CA125, KLK10 can improve the 
diagnostic sensitivity by about 20% compared to that of 
CA125 alone. 
Cytogenetics 
No cytogenetic abnormalities are identified so far. 
Hybrid/Mutated Gene 
Not identified so far. 
Various cancers with down regulated 
KLK10 
Disease 
Breast cancer, testicular cancer, leukemia, and prostate 
cancer. 
Prognosis 
In contrast to ovarian cancer, KLK10 is down regulated 
in these malignancies, with breast cancer as a 
prototype. Several lines of evidence have demonstrated 
that KLK10 is progressively down regulated during 
breast cancer development. In a clinical study, it is 
observed that essentially all normal breast specimens 
had KLK10 expression, whereas about 46% of ductal 
carcinoma in situ (DCIS) and the majority of 
infiltrating ductal carcinoma (IDC) had no detectable 
KLK10 expression. More importantly, the KLK10 
negative-DCIS was found to subsequently develop to 
IDC. In in vitro studies, it has been shown that KLK10 
is expressed in normal breast epithelial cells but 
dramatically reduced in breast cancer cell lines. 
Moreover, reintroduction of KLK10 expression into 
these cancer cells can suppress their tumorigenecity in 
nude mice. KLK10 was thus considered to function as a 
tumor suppressor in breast cancer. The mechanisms 
governing the down regulation of KLK10 in breast 
cancer is not clear. One explanation is CpG island 
hypermethylation of exon 3, as demonstrated in a 
number of cancer cell lines. Noteworthy, expression of 
KLK10 is modulated by some steroid hormones and 
retinoid acid. They may, under certain conditions, also 
contribute to the aberrant expression of KLK10 in 
tumor tissues. However, the paradoxical expression of 
KLK10 in different types of tumors remains obscure. 
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